Damage to the spinal cord or its nerves, frequently brought on by illness, trauma, or degeneration, is known as a spinal cord injury (SCI). Movement, sensation, or autonomic functions below the damage site may be temporarily or permanently lost because of this disruption in brain-body communication. Depending on the location and severity of the damage, SCIs can be either complete or partial, resulting in different levels of paralysis, numbness, and loss of bladder or bowel control. The spinal cord injury pipeline analysis by Expert Market Research focuses on various treatment options for this disease. Recent developments include RNA-based therapies, immune modulators, and gene editing techniques. Increasing research, improved diagnostics, and innovative treatments are expected to fuel the growth of spinal cord injury drug candidates in the coming years.
Major companies involved in the spinal cord injury pipeline analysis include AbbVie, and Neuroplast among others.
Leading drugs currently in the pipeline include Elezanumab, Neuro-Cells, and others.
Advancements in novel therapies are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Spinal Cord Injury Pipeline Analysis Report by Expert Market Research gives comprehensive insights into spinal cord injury therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for spinal cord injury. The spinal cord injury report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The spinal cord injury pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with spinal cord injury treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to spinal cord injury.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathophysiology of spinal cord injuries begins with a basic mechanical insult that results in instantaneous cell death, which is followed by secondary injury mechanisms. These include immune cell infiltration, oxidative stress, neuroinflammation, and excitotoxicity, which result in further necrosis and apoptosis of neurons and glial cells. Axonal regeneration is hampered by the glial scarring and demyelination that follow, and persistent tissue deterioration and poor functional recovery are caused by chronic inflammation and autoimmune.
The goals of spinal cord injury treatment are to stabilize the spine, stop more harm, and encourage healing. Immobilization and surgery to stabilize vertebrae or remove compressive factors are part of emergency care. Physical and occupational therapy combined with rehabilitation promotes adaptability and functional recovery. It is crucial to control discomfort, use assistive technology, and avoid consequences like pressure ulcers or infections. Stem cells are one of the experimental treatments being researched for nerve regeneration and repair.
Millions of people worldwide suffer from spinal cord injury, with prevalence estimates varying by location from 236 to 1,298 per million. According to the World Health Organization, there were around 15.4 million people with spinal cord injury globally in 2021. Men were more likely than women to be affected. In recent decades, the prevalence has gone up, which is indicative of both an increase in incidence and better survival rates for those with spinal cord injury.
This section of the report covers the analysis of spinal cord injury drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total spinal cord injury clinical trials.
In the spinal cord injury pipeline, maximum number of candidates are present in Phase II with 60% of the candidates followed by Phase III and Phase IV with 20% of candidates in each demonstrating a wide spectrum of development stages and progress toward potential treatments.
The drug molecule categories covered under the spinal cord injury pipeline analysis include small molecules, RNA-based therapies, peptides, biologics, and gene editing therapies. The spinal cord injury report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for spinal cord injury.
Monoclonal antibodies are emerging as promising agents in the spinal cord injury pipeline. For example, Elezanumab, a human monoclonal antibody designed to target and neutralize Repulsive Guidance Molecule A (RGMa), is involved in inhibiting nerve regeneration.
The EMR report for the spinal cord injury pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Spinal Cord Injury clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for spinal cord injury. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal cord injury drug candidates.
AbbVie created the human monoclonal antibody Elezanumab (ABT-555), which targets the neural regeneration inhibitor repulsive guidance molecule A (RGMa). For patients with spinal cord injuries, it is presently being assessed in Phase II clinical research. Elezanumab seeks to improve functional recovery and encourage axonal development in the central nervous system by neutralizing RGMa. It has received fast track and orphan drug designations from the U.S. FDA.
Neuroplast created the autologous stem cell treatment known as Neuro-Cells to treat traumatic spinal cord injury (TSCI). Hematopoietic and mesenchymal stem cells from the patient's own bone marrow are used to control inflammation, lower apoptosis, and encourage brain regeneration. In Phase II and III trials, Neuro-Cells, when administered intrathecally during the sub-acute phase after damage, demonstrated exceptional safety and tolerability; no adverse events connected to the product were documented.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Spinal Cord Injury Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for spinal cord injury. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into spinal cord injury collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share